Safety and efficacy of AIN457 in patients with active non-infectious uveitis

Phase 3

• Conditions: non-infectiouse uveitis

• Registration Number: JPRN-jRCT2080221051
• Lead Sponsor: ovartis Pharma K.K.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: All
• Target Recruitment: 208

Inclusion Criteria

Male and female subjects 18 years of age or older
- Patients with diagnosis of chronic non-infectious intermediate uveitis, posterior uveitis or panuveitis in at least one eye
- Evidence of active intermediate, posterior or panuveitis at screening and baseline in at least one eye
- Requirement for any of the immunosuppressive therapies for the treatment or prevention of uveitis

Exclusion Criteria

- Patients with a primary diagnosis of Behcet's disease or anterior uveitis
- Any intermediate uveitis, posterior uveitis or panuveitis in which the manifestation(s) of the active intraocular inflammatory disease may spontaneously resolve or that are not characterized by the presence of either anterior chamber cells or vitritis such as the white dot retino-choroidopathies
- Patients with infectious uveitis

Study & Design

• Study Type: Interventional
• Study Design: Not specified